Ira Jacobson MD
Hepatology & Liver Transplantation
Professor of Medicine, NYU School of Medicine
Join to view full profile
530 1st AveFl 7New York, NY 10016
Phone+1 212-263-0474
Fax+1 212-263-0475
Dr. Jacobson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ira Jacobson is a distinguished gastroenterologist based in New York, specializing in hepatology and liver transplantation. He completed his medical education at Columbia University Vagelos College of Physicians and Surgeons and his fellowship in gastroenterology at Massachusetts General Hospital. Currently, he serves as the Director of Hepatology at NYU Langone Health and holds various influential positions in academia and medical institutions, including roles at Weill Cornell Medicine and Icahn School of Medicine at Mount Sinai. His research interests focus on hepatology, viral hepatitides, and liver-related diseases, with numerous publications in prestigious journals. Dr. Jacobson has been involved in multiple clinical trials and has received numerous professional accolades, including being a Fellow at both the American College of Physicians and the American Gastroenterological Association.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 1982 - 1984- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1981 - 1984
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979
Yale UniversityB.S., Summa Cum Laude, 1971 - 1975
Certifications & Licensure
NY State Medical License 1984 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2017
- CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2012-2014, 2017
Clinical Trials
Publications & Presentations
PubMed
- Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey.Tatyana Kushner, Maria Buti, Mohamed El-Kassas, Yusuf Yilmaz, Hirokazu Takahashi
Liver International. 2026-05-01 - 11 citationsSafety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.Cynthia Levy, George F Abouda, Bahri M Bilir, Alan Bonder, Christopher L Bowlus
Journal of Hepatology. 2026-01-01 - 1 citationsBest practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.Markus Cornberg, Fabien Zoulim, Robert Gish, Ira M Jacobson, Tatyana Kushner
Antiviral Therapy. 2025-10-01
Journal Articles
- Diagnosis and Management of Primary Biliary CholangitisZobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
- Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment FailureIra Jacobson, MD, Hepatology
- Hepatitis C virus RNA functionally sequesters miR-122Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Rice CM, Darnell RB, Cell, 1/12/2015
Books/Book Chapters
Abstracts/Posters
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1) a phase 3, random...Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beaumont-Ma..., Lancet, 1/3/2014
- Sapphire II: Phase 3 Placebo controlled study of Interferon-free, 12-week regimen of ABT-450/R/ABT-267 ABT-333. And Ribavirin treatment-experienced adults with Hepatit...Zeuzem S, Baykal T, Marinho R.T, Poordad F., Bourliere M, Sulkowski M, Wedemeyer H., Tam E., Desmond P., Jensen D., Di Bisceglie A.M., Varunok P., Hassanein T, Xiong J..., Journal of Hepatology, 1/1/2014
- Safety and efficacy of MK-5172 plus Peginterferon Alfa-2b and Rivacirin (PR) in cirrhotic and non-cirrhotic treatment-naïve patients with hepatitis C virus (HCV) genot...Hezode C, Bruno S, Serfaty P, Kwo A, Zhou A, Gilbert C, Hwang P, Wahl J, Robertson M.N., Mobashery N, Journal of Hepatology, 1/1/2014
Lectures
- Current State of the Are in HCV Therapy1/1/2015
- Curren Therapy for HCVKansas City, KS - 1/1/2015
- All-Oral Therapies for HCVLa Jolla, CA - 1/1/2015
Other
- Update on hepatitis C virus in HIV/HCV co-infectionwith Talal AH, National AIDS treatment advocacy program
http://www.natap.org/2001/jun/current061101.htmwwnatap.org/2001/jun/current061101
1/1/2001 - Advice for testing and treatment of hepatitis Cwith Russo M, Medical Society of the State of New York
1/1/1999 - ERCP and the pancreasJacobson IM, Clinical Advances in Gastroenterology, audiotape update program of American College of Gastroenterol
1/1/1994
Press Mentions
Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory TherapeuticsDecember 6th, 2018
Ribavirin Beneficial for Patients with Hepatitis C Genotype 3November 29th, 2018
Renowned Liver Disease Specialist Named Director of Hepatology at NYU Langone HealthAugust 16th, 2017
Grant Support
- Placebo-Controlled, Single Ascending Dose Study To Evaluate The Safety, TolerabiNational Center For Research Resources2006
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
